Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation
Pricing And Value Questions Dominate
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.
